Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects

Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Transl Psychiatry
Autores principales: Nam, H W, Karpyak, V M, Hinton, D J, Geske, J R, Ho, A M C, Prieto, M L, Biernacka, J M, Frye, M A, Weinshilboum, R M, Choi, D-S
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4564571/
https://ncbi.nlm.nih.gov/pubmed/26285131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2015.120
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares